PBI
69
4
LH
43
-2
TDC
80
4
BWA
48
2
GT
62
6
UNP
52
7
CMA
61
5
CAH
48
-5
SYY
53
4
NDAQ
62
2
INTU
56
-4
CTSH
56
2
URBN
56
14
PAYX
53
2
MCD
52
2
KMB
39
2
MET
72
5
UA
50
-9
LMT
34
2
CINF
53
2
PBI
69
4
LH
43
-2
TDC
80
4
BWA
48
2
GT
62
6
UNP
52
7
CMA
61
5
CAH
48
-5
SYY
53
4
NDAQ
62
2
INTU
56
-4
CTSH
56
2
URBN
56
14
PAYX
53
2
MCD
52
2
KMB
39
2
MET
72
5
UA
50
-9
LMT
34
2
CINF
53
2
Financhill
Back

Madrigal Pharmaceuticals 10K Form

Buy
64

MDGL
Madrigal Pharmaceuticals

Last Price:
347.27
Seasonality Move:
43.27%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MDGL News And Ratings

See the #1 stock for the next 7 days that we like better than MDGL

MDGL Financial Statistics

Sales & Book Value

Annual Sales: $150K
Cash Flow: $-67.76M
Price / Cash Flow: 0
Annual Sales: $35.64
Price / Book: 9.75

Profitability

EPS (TTM): -25.12000
Net Income (TTM): $-518.67M
Gross Margin: $0
Return on Equity: -89.04%
Return on Assets: -62.74%

Madrigal Pharmaceuticals Earnings Forecast

Key Madrigal Pharmaceuticals Financial Ratios

  • The Selling, General & Administrative Expenses for MDGL have been equal to 7,786.67% of Gross Profit Margin.
  • The Interest Expense is -3.40% of Operating Income.
  • Per Share Earnings over the last 23 years have been positive in 8 years.

Madrigal Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: MDGL
CUSIP: 558868
Website: madrigalpharma.com

Debt

Debt-to-Equity Ratio: 0.15
Current Ratio: 5.98
Quick Ratio: 5.79

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

MDGL Technical Analysis vs Fundamental Analysis

Buy
64
Madrigal Pharmaceuticals (MDGL) is a Buy

Is Madrigal Pharmaceuticals a Buy or a Sell?